ResMed (NYSE: RMD) reported Q4 EPS of $0.74, in-line with the analyst estimate of $0.74. Revenue for the quarter came in at $518.6 million versus the consensus estimate of $513.97 million.

For earnings history and earnings-related data on ResMed (RMD) click here.